Press release
CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to Increasing Number of Patients Undergoing Chemotherapy
Read Report Overview @ https://www.transparencymarketresearch.com/cinv-market.html
Based on the major drugs available on the market currently, the report segments the CINV existing drugs market as follows: Akynzeo (netupitant-palonosetron FDC), Aloxi (palonosetron), Zofran Generic (ondansetron), Emend (aprepitant), and Kytril Generic (granisetron). Drugs in the pipeline that are studied in the report include: Rolapitant and SUSTOL (granisetron injection extended release).
It is expected that the incidence rate of cancer will soar 17.1 million by 2020. With a growing prevalence rate of cancer across the world, more and more patients are expected to undergo chemotherapy. This alone will be a high-impact driver for the global CINV drugs market. Studies show that nearly 30% of all people suffering from cancer are advised to undergo chemotherapy. Of these, about 70% to 80% patients suffer from CINV.
In the light of these factors, the CINV existing and pipeline drugs market will receive a boost with the expected launch of new drugs such as SUSTOL (APF-530) and rolapitant. The efficacy of pipeline drugs that are at the clinical study stage has been reported to be higher than that of the current CINV treatment drugs on the market. This will likely lead to physicians prescribing newer drugs more as opposed to existing drugs.
Request for the Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776
The growth of the CINV drugs market is expected to be hampered to some degree by the patents of two leading drugs – Aloxi and Emend – lapsing. This will cause a dip in the revenue of CINV drugs over the forecast period of the report, which ranges from 2014 to 2020.
Studying the market from the regional perspective, the report states that North America was the largest CINV drugs market in 2013 and will remain in this position until 2020. The CINV drugs market in North America will receive a massive boost from rolapitant and SUSTOL. Europe followed North America in terms of CINV drugs revenue in 2013. The alarming increase in cancer cases reported from Asia Pacific and Rest of the World will enable the CINV drugs market to grow vigorously in these markets.
Companies that have secured a competitive edge in the global CINV drugs market are: Helsinn Holding S.A., GlaxoSmithKline plc, Merck & Co., Inc. Heron Therapeutics, Inc., and Tesaro, Inc.
Obtain the Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=776
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to Increasing Number of Patients Undergoing Chemotherapy here
News-ID: 1180186 • Views: …
More Releases from Transparency Market Research
Textile Chemicals Market to Reach USD 46.1 Billion by 2036, Growing at 3.7% CAGR …
The global textile chemicals market was valued at US$ 30.8 billion in 2025 and is projected to reach US$ 46.1 billion by 2036, expanding at a compound annual growth rate (CAGR) of 3.7% from 2026 to 2036. Market expansion is supported by the growing consumption of apparel, increasing demand for functional textiles, and the adoption of environmentally responsible textile manufacturing practices.
Textile chemicals play an essential role throughout textile production, including…
Dimethyl Sulfoxide Market to Reach USD 336.9 Million by 2036, Driven by Pharmace …
The global dimethyl sulfoxide (DMSO) market is projected to grow from USD 186.9 million in 2025 to USD 336.9 million by 2036, registering a compound annual growth rate (CAGR) of 5.5% during the forecast period from 2026 to 2036. This growth is expected to be supported by rising demand from pharmaceutical and biopharmaceutical manufacturers, increasing applications in cell preservation, and expanding use in electronics and semiconductor production. The growing need…
Ion Exchange Membrane Market to Reach USD 2.39 Billion by 2036, Driven by Green …
The global Ion Exchange Membrane Market was valued at US$ 1.20 billion in 2025 and is projected to reach US$ 2.39 billion by 2036, expanding at a compound annual growth rate (CAGR) of 6.4% from 2026 to 2036. Market growth is driven by rising demand for proton exchange membrane (PEM) electrolyzers, increasing investments in green hydrogen production, expansion of chlor-alkali manufacturing capacity, and growing requirements for advanced water treatment and…
Kidney Dialysis Equipment Market to Reach USD 34.5 Billion by 2036, Driven by Ri …
Kidney Dialysis Equipment Market Outlook 2036
The global kidney dialysis equipment market was valued at USD 18.8 Billion in 2025 and is projected to reach USD 34.5 Billion by the end of 2036, expanding at a CAGR of 6.3% from 2026 to 2036. Market growth is driven by the rising prevalence of chronic kidney disease, increasing cases of kidney failure, and growing demand for center-based and home-based dialysis. Technological advancements in…
More Releases for CINV
Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vom …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market encompassing chemotherapy-induced nausea and vomiting treatments has witnessed substantial expansion, projected to increase its valuation from $2.92 billion in 2024 to $3.13 billion in 2025, reflecting a compound annual growth…
CINV Treatment Market to Reach USD 3.9 Billion by 2034
Pune, India, November 11, 2025 - The global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market is projected to grow from USD 2.6 billion in 2024 to USD 3.9 billion by 2034, registering a CAGR of 4.1 %, according to Exactitude Consultancy. Rising cancer incidence, increasing chemotherapy adoption, and development of next-generation serotonin (5-HT3) and neurokinin-1 (NK1) receptor antagonists are driving global market expansion.
Download Full PDF Sample Copy of Market Report…
Emerging Trends Influencing The Growth Of The Chemotherapy-Induced Nausea and Vo …
The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Expected to Be by 2034?
There has been a notable growth in the market size of chemotherapy-induced nausea and vomiting (CINV)…
Key Influencer in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market 202 …
How Are the key drivers contributing to the expansion of the chemotherapy-induced nausea and vomiting (cinv) market?
The escalating cases of cancer are expected to foster the expansion of the market for chemotherapy-induced nausea and vomiting (CINV). This rise is due to the uncontrolled development and spread of cancer cells in the body. As cancer prevalence increases, there's an increased drive to produce highly effective and specific anti-emetic treatments, which would…
CINV Existing and Pipeline Drugs Market : Growing number of patients undergoing …
The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” the business intelligence firm says that…
CINV Existing and Pipeline Drugs Market : Future Demand and Growth Analysis
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV). CINV significantly affects the treatment of patients undergoing chemotherapy. Two major subtypes of CINV are acute CINV (occurs within 24 hours of chemotherapy) and delayed CINV (occurs between 24 hours and five days after treatment). Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend…
